-
1.发明申请公开(公告)号：US20120322732A1
公开(公告)日：2012-12-20
申请号：US13551648
申请日：2012-07-18
申请人： Beat Amrein , Stefan Foser , Kurt Lang , Friedrich Metzger , Joerg Regula , Andreas Schaubmar , Friederike Hesse , Klaus-Peter Kuenkele , Martin Lanzendoerfer
发明人： Beat Amrein , Stefan Foser , Kurt Lang , Friedrich Metzger , Joerg Regula , Andreas Schaubmar , Friederike Hesse , Klaus-Peter Kuenkele , Martin Lanzendoerfer
CPC分类号： A61K47/60 , C07K14/475 , C07K14/65
摘要： A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.
摘要翻译： 由胰岛素样生长因子-1（IGF-I）变体和一个或两个聚（乙二醇）基团组成的缀合物，其特征在于所述IGF-1变体在至多三个氨基酸处具有氨基酸改变 野生型IGF-I氨基酸序列的酸性位置27,37,65,68，使得一个或两个所述氨基酸是赖氨酸，氨基酸27是极性氨基酸而不是赖氨酸，通过 公开了所述赖氨酸和所述聚（乙二醇）基团的伯氨基的总分子量为20至100kDa。 该缀合物可用于治疗神经变性疾病如阿尔茨海默病。
-
2.发明申请公开(公告)号：US20060154865A1
公开(公告)日：2006-07-13
申请号：US11313101
申请日：2005-12-20
申请人： Beat Amrein , Stefan Foser , Kurt Lang , Friedrich Metzger , Joerg Regula , Andreas Schaubmar , Friederike Hesse , Klaus-Peter Kuenkele , Martin Lanzendoerfer
发明人： Beat Amrein , Stefan Foser , Kurt Lang , Friedrich Metzger , Joerg Regula , Andreas Schaubmar , Friederike Hesse , Klaus-Peter Kuenkele , Martin Lanzendoerfer
CPC分类号： A61K47/60 , C07K14/475 , C07K14/65
摘要： A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.
摘要翻译： 由胰岛素样生长因子-1（IGF-I）变体和一个或两个聚（乙二醇）基团组成的缀合物，其特征在于所述IGF-1变体在最多三个氨基酸处具有氨基酸改变 野生型IGF-I氨基酸序列的酸性位置27,37,65,68，使得一个或两个所述氨基酸是赖氨酸，氨基酸27是极性氨基酸而不是赖氨酸，通过 公开了所述赖氨酸和所述聚（乙二醇）基团的伯氨基的总分子量为20至100kDa。 该缀合物可用于治疗神经变性疾病如阿尔茨海默病。
-
3.发明申请公开(公告)号：US20110009317A1
公开(公告)日：2011-01-13
申请号：US12791904
申请日：2010-06-02
申请人： Beat Amrein , Stefan Foser , Kurt Long , Friedrich Metzger , Joerg Regula , Andreas Schaubmar , Friederike Hesse , Klaus-Peter Kuenkele , Martin Lanzendoerfer
发明人： Beat Amrein , Stefan Foser , Kurt Long , Friedrich Metzger , Joerg Regula , Andreas Schaubmar , Friederike Hesse , Klaus-Peter Kuenkele , Martin Lanzendoerfer
CPC分类号： A61K47/60 , C07K14/475 , C07K14/65
摘要： A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is/are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.
摘要翻译： 由胰岛素样生长因子-1（IGF-I）变体和一个或两个聚（乙二醇）基团组成的缀合物，其特征在于所述IGF-1变体在至多三个氨基酸处具有氨基酸改变 野生型IGF-I氨基酸序列的酸性位置27,37,65,68，使得一个或两个所述氨基酸是赖氨酸，氨基酸27是极性氨基酸而不是赖氨酸，通过 公开了所述赖氨酸和所述聚（乙二醇）基团的伯氨基的总分子量为20至100kDa。 该缀合物可用于治疗神经变性疾病如阿尔茨海默病。
-
-
搜索结果
3 条记录 (耗时 0.027 秒)
